Ustby, Donarski lead No. 16 North Carolina women over Villanova 53-36 in Battle 4 Atlantis semifinal
Women will for the first time make up a majority of state legislators in Colorado and New Mexico next year, but at least 13 states saw losses in female representation after the November election, according to a count released Thursday by the Rutgers Center for American Women and Politics. While women will fill a record number of state legislative seats in 2025, the overall uptick will be slight, filling just over third of legislative seats. Races in some states are still being called. "We certainly would like to see a faster rate of change and more significant increases in each election cycle to get us to a place where parity in state legislatures is less novel and more normal," said Kelly Dittmar, director of research at the CAWP, which is a unit of the Eagleton Institute of Politics at Rutgers University. As of Wednesday, at least 2,450 women will serve in state legislatures, representing 33.2% of the seats nationwide. The previous record was set in 2024 with 2,431 women, according to the CAWP. The number of Republican women, at least 851, will break the previous record of 815 state lawmakers set in 2024. "But still, Republican women are very underrepresented compared to Democratic women," Debbie Walsh, director of the CAWP, said. From left, House Maj. Whip Reena Szczepanski, D-Santa Fe, Rep. D. Wonda Johnson, D-Church Rock and Rep. Cristina Parajon, D-Albuquerque, talk July 18 before the start of a special session, in Santa Fe, N.M. By the most recent count, 19 states will have increased the number of women in their state legislatures, according to the CAWP. The most notable increases were in New Mexico and Colorado, where women will for the first time make up a majority of lawmakers. In New Mexico, voters sent an 11 additional women to the chambers. Colorado previously attained gender parity in 2023 and is set to tip over to a slight female majority in the upcoming year. The states follow Nevada, which was the first in the country to see a female majority in the legislature following elections in 2018. Next year, women will make up almost 62% of state lawmakers in Nevada, far exceeding parity. Women in California's Senate will make up the chamber's majority for the first time in 2025 as well. Women also made notable gains in South Dakota, increasing its number by at least nine. Four of South Carolina's Sister Senators, from left, Sen. Margie Bright Matthews, D-Walterboro, Sen. Mia McLeod, I-Columbia, Sen. Katrina Shealy, R-Lexington, and Sen. Penry Gustafson, R-Camden, stand in front of the Senate on June 26 with their John F. Kennedy Profile in Courage award in Columbia, S.C. At least thirteen states emerged from the election with fewer female lawmakers than before, with the most significant loss occurring in South Carolina. This year, the only three Republican women in the South Carolina Senate lost their primaries after they stopped a total abortion ban from passing. Next year, only two women, who are Democrats, will be in the 46-member Senate. No other state in the country will have fewer women in its upper chamber, according to the CAWP. Women make up 55% of the state's registered voters. Half the members in the GOP dominated state were elected in 2012 or before, so it will likely be the 2040s before any Republican woman elected in the future can rise to leadership or a committee chairmanship in the chamber, which doles out leadership positions based on seniority. A net loss of five women in the legislature means they will make up only about 13% of South Carolina's lawmakers, making the state the second lowest in the country for female representation. Only West Virginia has a smaller proportion of women in the legislature. West Virginia stands to lose one more women from its legislative ranks, furthering its representation problem in the legislature where women will make up just 11% of lawmakers. Many women, lawmakers and experts say that women's voices are needed in discussions on policy, especially at a time when state government is at its most powerful in decades. Walsh, director of the CAWP, said the new changes expected from the Trump administration will turn even more policy and regulation to the states. The experiences and perspectives women offer will be increasingly needed, she said, especially on topics related to reproductive rights, healthcare, education and childcare. "The states may have to pick up where the federal government may, in fact, be walking away," Walsh said. "And so who serves in those institutions is more important now than ever." November 7, 2024: Trump Victory Stay up-to-date on the latest in local and national government and political topics with our newsletter.Fly To The Moon And Beyond These School Holidays At Stardome
PONTE VEDRA, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace” or the "Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases combining IntelliGuideTM PSI technology with the Adductoplasty® System for a CT-based, patient specific correction personalized to the patient's unique midfoot deformity. IntelliGuideTM PSI, incorporating RedPointTM technology, is the first and only patient-specific cut guide system available for correction of bunion and/or midfoot deformities in the U.S. IntelliGuideTM PSI provides an AI-enabled software approach to convert a patient's CT-scan to a pre-operative surgical plan and produce a 3D-printed cut guide specific to the patient's deformity for efficient and personalized intra-operative guidance. It is estimated that midfoot deformities, such as metatarsus adductus, may occur in up to 30% of bunion patients. 1,2 Treace has now initiated a limited market release of IntelliGuideTM PSI for the Adductoplasty® Procedure and plans to expand surgeon access of IntelliGuideTM for both the Lapiplasty® and Adductoplasty® procedures progressively over the coming months with full market release expected within the first half of 2025. "IntelliGuideTM PSI further advances our market leadership position in the surgical management of bunion and midfoot deformities, extending the established benefits of PSI personalized approaches to our Lapiplasty® and Adductoplasty® Procedures,” said John T. Treace, CEO, Founder and Board Member of Treace. "We look forward to further building out our ecosystem of enabling digital technologies as part of our strategy to provide a comprehensive portfolio of bunion and related midfoot solutions to address the evolving needs of our surgeon customers and patients.” Eric Kuhlman, DPM of Center for Spine & Orthopedics in Denver, who performed an initial IntelliGuideTM Adductoplasty® case commented, "This technology is going to revolutionize the way that I approach treating patients with bunion and related midfoot deformities. The virtual planning process helped me fully visualize the complex three-dimensional metatarsus adductus midfoot correction before stepping foot in the OR and the 3D-printed cut guides added a new level of intra-operative precision, efficiency, and confidence to the procedure. Just as PSI has advanced other areas of orthopedics, I expect IntelliGuideTM PSI to rapidly expand our understanding and treatment of these common, yet challenging foot deformities.” Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company's expectations of innovation, product commercialization, market performance, and growth. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace's public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. Internet Posting of Information Treace routinely posts information that may be important to investors in the "Investor Relations” section of its website at www.treace.com . The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System - a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlateTM Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com . To learn more about Treace, connect with us on LinkedIn , X , Facebook and Instagram . 1. Aiyer AA, et al. Foot Ankle Int. 2014; 35:1292-1297. 2. Gribbin CK, et al. Foot Ankle Int. 2017; 38:14-19. Contacts : Treace Medical Concepts Mark L. Hair Chief Financial Officer [email protected] (904) 373-5940 Investors : Gilmartin Group Vivian Cervantes [email protected]
SentinelOne (NYSE:S) Reports Q3 In Line With Expectations But Stock Drops 10.7%